Analysis of the cost of population screening for haemochromatosis using biochemical and genetic markers

Journal of Hepatology

Volumn 27, Issue 3, 1997, Pages 517-524

  Bassett, Mark L ^a   Leggett, Barbara A ^b   Halliday, June W ^b   Webb, Sonja ^b   Powell, Lawrie W ^b  

^a CANBERRA HOSPITAL   (Australia)

^b ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

Author keywords

Cost; Genetic testing; Haemochromatosis screening; Transferrin saturation

Indexed keywords

TRANSFERRIN;

ARTICLE; AUTOSOMAL RECESSIVE DISORDER; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DATA ANALYSIS; DNA DETERMINATION; EARLY DIAGNOSIS; GENETIC ANALYSIS; GENETIC MARKER; HEMOCHROMATOSIS; HUMAN; HUMAN CELL; IRON OVERLOAD; MASS SCREENING; PRIORITY JOURNAL; TISSUE INJURY;

EID: 0030766989     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(97)80357-1     Document Type: Article

References (26)

1. Edwards CQ, Griffen LM, Goldgar D, Drummond C, Skolnick MH, Kushner JP. Prevalence of hemochromatosis among 11,065 presumably health blood donors. N Engl J Med. 318:1988;1355-1362.
2. Leggett BA, Halliday JW, Brown NN, Bryant S, Powell LW. Prevalence of haemochromatosis amongst asymptomatic Australians. Br J Haematol. 74:1990;525-530.
3. Bassett ML, Doran TJ, Halliday JW, Bashir HV, Powell LW. Idiopathic hemochromatosis: demonstration of homozygous-heterozygous mating by HLA typing of families. Hum Genet. 60:1982;352-356.
4. Wiggers P, Dalhoj J, Hyltoft Petersen P, Blaabjerg O, Horder M. Screening for haemochromatosis: influence of analytical imprecision, diagnostic limit and prevalence on test validity. Scand J Clin Lab Invest. 51:1991;143-148.
5. Bell H, Raknerud N, Bosnes V, Hansen T, Halvorsen R, Try K, et al. High prevalence of hereditary hemochromatosis in first time Norwegian healthy blood donors [abstract]. Gastroenterology. 108:1995;1042.
6. Smith BN, Kantrowitz, Grace ND, Greenberg MS, Patton TJ, Sorger K, et al. Prevalence of genetic hemochromatosis among employees of a large Boston corporation [abstract]. Hepatology. 20:1994;401.
7. Balan V, Baldus W, Fairbanks V, Michels V, Burritt M, Klee G. Screening for hemochromatosis: a cost-effectiveness study based on 12,258 patients. Gastroenterology. 107:1994;453-459.
8. Dadone MM, Kushner JP, Edwards CQ, Bishop DT, Skolnick MH. Hereditary hemochromatosis. Analysis of laboratory expression of the disease by genotype in 18 pedigrees. Am J Clin Pathol. 78:1982;196-207.
9. Bassett ML, Halliday JW, Bryant S, Dent O, Powell LW. Screening for hemochromatosis. Ann N Y Acad Sci. 526:1988;274-289.
10. Edwards CQ, Kushner JP. Screening for hemochromatosis. N Engl J Med. 328:1993;1616-1620.
11. Feder JN, Gnirke A, Thomas W, Tsuchihashi Z, Ruddy DA, Basava A, et al. A novel MHC class-I like gene is mutated in patients with hereditary hemochromatosis. Nature Genet. 13:1996;399-08.
12. Jazwinska EC, Cullen LM, Busfield F, Pyper WR, Webb SI, Powell LW, et al. Haemochromatosis and HLA-H. Nature Genet. 13:1996;249-252.
13. Phatak PD, Guzman G, Woll JE, Robeson A, Phelps CE. Cost-effectiveness of screening for hereditary hemochromatosis. Arch Intern Med. 154:1994;769-776.
14. Baer DM, Simons JL, Staples R, Rumore GJ, Morton CJ. Hemochromatosis screening in asymptomatic ambulatory men 30 years of age and older. Am J Med. 98:1995;964-968.
15. Adams PC, Gregor JC, Kertesz AE, Valberg LS. Screening blood donors for hereditary hemochromatosis: decision analysis model based on a 30-year database. Gastroenterology. 109:1995;177-188.
16. Bassett ML, Halliday JW, Powell LW. Value of hepatic iron measurements in early hemochromatosis and determination of the critical iron level associated with fibrosis. Hepatology. 6:1986;24-29.
17. Lindor KD, Bru C, Jorgensen RA, Rakela J, Bordas JM, Gross JB, et al. The role of ultrasonography and automatic-needle biopsy in outpatient percutaneous liver biopsy. Hepatology. 23:1996;1079-1083.
18. Bassett ML, Halliday JW, Powell LW. HLA typing in idiopathic hemochromatosis: distinction between homozygotes and heterozygoes with biochemical expression. Hepatology. 1:1981;120-126.
19. Bird DL, Fox JN, Ashley S, Imrie MJ. Results of the first year of breast cancer screening in a district hospital. Br J Surg. 79:1992;922-944.
20. Abramson N, Cotton S, Eckels R, Baldock J. Voluntary screening programme for prostate cancer: detection rate and cost. South Med J. 87:1994;785-788.
21. Trehu EG, Cooper JN. Cost of screening for colorectal cancer: results of a community mass screening program and review of the literature. South Med J. 85:1992;248-254.
22. Gregg RG, Wilfond BS, Farrell PM, Laxova A, Hassemer D, Mischler EH. Application of DNA analysis in a population-screening program for neonatal diagnosis of cystic fibrosis (CF): comparison of screening protocols. Am J Hum Genet. 52:1993;616-626.
23. Bradbear RA, Bain C, Siskind V, Schofield FD, Webb S, Axelson EM, et al. Cohort study of internal malignancy in genetic hemochromatosis and other chronic nonalcoholic liver diseases. JNCI. 75:1985;81-84.
24. Niederau C, Fischer R, Purschel A, Stremmel W, Haussinger D, Strohmeyer G. Long-term survival in patients with hereditary hemochromatosis. Gastroenterology. 110:1996;1107-1109.
25. Adams PC, Speechley M, Kertesz AE. Long-term survival analysis in hereditary hemochromatosis. Gastroenterology. 101:1991;368-372.
26. Wilson JM, Junger G. The principles and practice of screening for disease. 34:1968;26-39 Public Health Papers World Health Organization.